Neuren Media and Analyst Coverage, page-1128

Even if you don't plan to fund the phase three trials yourselves, you want the market, your competitors and potential acquirers to think you have the option to go alone. Jon is planning the first P3 for 2591 knowing that something is likely to occur (partnership for all rights or take over).

It would be prudent to know what funding options are available should we go alone. It is managing the risk.

It is a bit like how the last CR on record for NEU was just prior to P3 results, even though we had sufficient cash in the bank and didn't "need" a CR.

Jon knew the outcome was probably good (milestone payment) but raising then would allow NNZ 2591 to progress regardless and if that situation occured, the company would have raised money at a much better market cap. At the time people were very upset about that CR, but even though the results were good I think it was a great move. Since then, we've not had a single CR and shareholders were rewarded very well.